In the News - Forbes - Tessier-Lavigne
COPY LINK
Genentech Brain Trust Leaves With $217 Million For New Startup To Fight Alzheimer’s And Parkinson’s
“Three former top researchers at Genentech, the legendary biotech that is now part of Roche Holding, have raised $217 million in venture capital to start a new company, Denali Therapeutics, focused on treating and curing neurodegenerative diseases like Alzheimer’s, ALS, and Parkinson’s. One co-founder, Denali’s chairman of the board of directors, is Marc Tessier-Lavigne, a well-known neuroscientist and president of Rockefeller University in New York.”
